(Q53652472)

English

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.

scientific article published in March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

6

object named as

Jos H Beijnen

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

Jan H M Schellens

5

object named as

Jan H M Schellens

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

author name string

Robert S Jansen

1

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

Hilde Rosing

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

Pierre W Wijermans

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

Ron J Keizer

4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

69

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

6

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

1457-1466

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

https://scigraph.springernature.com/pub.10.1007/s00280-012-1850-x

0 references

Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

DNA methylation as a therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Drug resistance to cytotoxic nucleoside analogues

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Decitabine dosing schedules.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Decitabine--bedside to bench

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1850-X

21 January 2018

Identifiers

10.1007/S00280-012-1850-X

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/22382880

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53652472&oldid=2143563687"